Android app Apple app link

Blueprint Medicines Corporation (BPMC) Analyst Forecast

NASDAQ Currency in USD Disclaimer
Add to Alerts ADD TO LIST

$129.46

north_east
$0.18 (0.14%)
Day's range
$129.46
Day's range
$129.46

Recent Analyst Forecasts and Stock Ratings

Date Brokerage Firm Analyst Name Price Target Price when Posted Upside/Downside
on Report Date		 Details
06/03/2025 Guggenheim Michael Schmidt $132.00 $127.60   3.45%
10/31/2024 Needham Ami Fadia $135.00 $89.24   51.28%
10/24/2024 UBS David Dai $88.00 $84.40   4.27%
09/19/2024 Stifel Nicolaus Bradley Canino $155.00 $90.94   70.44%
08/01/2024 Oppenheimer Matthew Biegler $130.00 $102.05   27.39%
07/29/2024 Barclays Peter Lawson $105.00 $112.19   -6.41%
07/08/2024 Oppenheimer Matthew Biegler $125.00 $116.55   7.25%
05/06/2024 Leerink Partners Andrew Berens $97.00 $107.19   -9.51%
05/03/2024 Raymond James Christopher Raymond $104.00 $106.29   -2.15%
05/03/2024 H.C. Wainwright Andrew Fein $135.00 $107.00   26.17%
11/01/2022 H.C. Wainwright Andrew Fein $70.00 $46.10   51.84%
09/06/2022 Oppenheimer Matthew Biegler $90.00 $70.66   27.37%
08/17/2022 Wells Fargo Derek Archila $41.00 $52.78   -22.31%
05/18/2022 Piper Sandler Christopher Raymond $65.00 $55.50   17.12%
01/31/2022 Morgan Stanley Michael Ulz $92.00 $79.16   16.22%
01/02/2022 Guggenheim Michael Schmidt $122.00 $110.08   10.83%
11/08/2021 Raymond James Dane Leone $133.00 $114.95   15.7%
07/28/2021 Goldman Sachs Salveen Richter $147.00 $84.74   73.47%
06/16/2021 Canaccord Genuity Arlinda Lee $120.00 $83.53   43.66%

Blueprint Medicines Corporation FAQ's

Blueprint Medicines Corporation has been rated by research analysts at Guggenheim, Scotiabank, Needham, UBS, Stifel Nicolaus, Oppenheimer in the past 90 days.

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.